ADA 2026: The Multi-Agonist and Oral Incretin Readouts, Summarized
ADA 2026 delivered phase 3 data on a triple GLP-1/GIP/glucagon agonist, a dual agonist, CagriSema and two oral agents. Here is the map.
Tagged
glucagon
3 notes in this topic
Triple GLP-1/GIP/Glucagon Agonists: Where the Research Stands
How a single peptide came to activate three proglucagon-family receptors, what phase 2 trials of the class reported, and what is still unknown.
GLP-1 vs. GIP vs. Glucagon Receptors: Why Multi-Agonism Emerged
Three related receptors, three different jobs. How the biology of GLP-1, GIP and glucagon receptors led from selective agonists to dual and triple agonists.
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.